- Home
- CR vs GH Comparison
CR vs GH Comparison
Compare CR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | GH |
|---|---|---|
| Founded | 1855 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.7B |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CR | GH |
|---|---|---|
| Price | $182.36 | $129.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $226.20 | $119.79 |
| AVG Volume (30 Days) | 468.9K | ★ 2.1M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | ★ 23.96 | 6.74 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $2,305,000,000.00 | $982,021,000.00 |
| Revenue This Year | $27.98 | $33.30 |
| Revenue Next Year | $5.76 | $28.27 |
| P/E Ratio | $158.97 | ★ N/A |
| Revenue Growth | 8.16 | ★ 32.88 |
| 52 Week Low | $159.58 | $39.70 |
| 52 Week High | $214.31 | $133.66 |
Technical Indicators
Market Signals| Indicator | CR | GH |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 77.90 |
| Support Level | $175.80 | $97.16 |
| Resistance Level | $184.91 | N/A |
| Average True Range (ATR) | 5.61 | 6.30 |
| MACD | 0.88 | 3.39 |
| Stochastic Oscillator | 83.52 | 89.87 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.